Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
This study is to determine if an oral drug called Ramipril can lower the chance of memory loss in patients with glioblastoma getting chemoradiation. Patients will take Ramipril during chemoradiation and continue until 4 months post-treatment. Memory loss will be assessed using several neurocognitive tests throughout the duration of the study.
Research Base: Wake Forest University Health Sciences
NCT ID: NCT03475186
NCI Protocol Number: WF-1801
Status: Active, not recruiting
For more information see ClinicalTrials.gov
Interventions
- Ramipril
Condition
Glioblastoma, Radiotherapy; Complications, Cognitive Decline, Chemoradiation
Trial Type
Supportive Care/Symptom Management/PROs
See a list of participating sites on ClinicalTrials.gov